EMAS position statement: Managing menopausal women with a personal or family history of VTE

Maturitas

Volumn 69, Issue 2, 2011, Pages 195-198

  Tremollieres, Florence ^a   Brincat, Marc ^b   Erel, C Tamer ^c   Gambacciani, Marco ^d   Lambrinoudaki, Irene ^e   Moen, Mette H ^f,g   Schenck Gustafsson, Karin ^h   Vujovic, Svetlana ⁱ   Rozenberg, Serge ^j   Rees, Margaret ^k  

^a Paul Sabatier University   (France)

^b MATER DEI HOSPITAL   (Malta)

^c ISTANBUL UNIVERSITY   (Turkey)

^d UNIVERSITY OF PISA   (Italy)

^e UNIVERSITY OF ATHENS   (Greece)

^f NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^g TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^h KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

ⁱ UNIVERSITY OF BELGRADE   (Serbia)

^j SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^k JOHN RADCLIFFE HOSPITAL   (United Kingdom)

more..

Author keywords

Menopausal women; Pulmonary embolism; Venous thromboembolism

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN; CONJUGATED ESTROGEN; DYDROGESTERONE; ESTROGEN; LIVER PROTEIN; MEDROXYPROGESTERONE ACETATE; NOMEGESTROL ACETATE; NORETHISTERONE; PEPTIDE; PREGNANE DERIVATIVE; PROGESTERONE; PROMEGESTONE; PROTHROMBIN; PROTHROMBIN ACTIVATION PEPTIDE; TESTOSTERONE; THROMBIN; UNCLASSIFIED DRUG; GESTAGEN;

ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING; COMBINATION CHEMOTHERAPY; DRUG CONTRAINDICATION; DRUG SAFETY; FAMILY HISTORY; GENE MUTATION; HORMONAL THERAPY; HUMAN; LIVER METABOLISM; MEDICAL EXPERT; MEDICAL HISTORY; META ANALYSIS (TOPIC); MONOTHERAPY; MULTICENTER STUDY (TOPIC); OBESITY; PORTAL VEIN BLOOD FLOW; POSTMENOPAUSE; PROTEIN METABOLISM; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RISK BENEFIT ANALYSIS; TREATMENT CONTRAINDICATION; VENOUS THROMBOEMBOLISM; CHEMICALLY INDUCED DISORDER; DISEASE PREDISPOSITION; ESTROGEN THERAPY; FEMALE; GENETICS; INTRADERMAL DRUG ADMINISTRATION; MEDICAL SOCIETY; MENOPAUSE; PATIENT SELECTION; PRACTICE GUIDELINE; RISK FACTOR;

ADMINISTRATION, CUTANEOUS; DISEASE SUSCEPTIBILITY; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MENOPAUSE; OBESITY; PATIENT SELECTION; PROGESTINS; RISK FACTORS; SOCIETIES, MEDICAL; VENOUS THROMBOEMBOLISM;

EID: 84863949639     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2011.03.011     Document Type: Article

References (40)

1. Straczek C, Oger E, Yon de Jonage-Canonico MB, et al. Prothrombotic mutations, hormone therapy, and venous thromboembolism among post-menopausal women: impact of the route of estrogen administration. Circulation 2005;112:3495-500. (Pubitemid 43739566)
2. Oger E. Incidence of venous thromboembolism: a community-based study in Western France, EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost 2000;83:657-60.
3. Naess IA, Christiansen SC, Romundstad P, et al. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007;5:692-9. (Pubitemid 46563566)
4. Deitelzweig SB, Johnson BH, Lin J, Schulman KL. Prevalence of clinical venous thromboembolism in the USA: current trends and future projections. Am J Hematol 2011;86:217-20.
5. Di Minno G, Mannucci P, Tufano A, et al. The first ambulatory screening on thromboembolism: a multicentre, cross-sectional, observational study on risk factors for venous thromboembolism. J Thromb Haemost 2005;3:1459-66. (Pubitemid 41725204)
6. Canonico M, Oger E, Conard J, et al. Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration, The ESTHER Study. J Thromb Haemost 2006;4:1259-65.
7. Grady D, Wenger N, Herrington D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease, The Heart and Estrogen/ progestin Replacement Study. Ann Intern Med 2000;132:689-96.
8. Simon T, Beau Yon de Jonage-Canonico M, Oger E, et al. Indicators of lifetime endogenous estrogen exposure and risk of venous thromboembolism. J Thromb Haemost 2006;4:71-6.
9. Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288:58-66. (Pubitemid 34705519)
10. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in health postmenopausal women. JAMA 2002;288:321-33.
11. Cushman M, Kuller LH, Prentice R, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004;292:1573-80. (Pubitemid 39314963)
12. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12. (Pubitemid 38489892)
13. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-77. (Pubitemid 46556472)
14. Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ Clin Res 2008;336:1227-31. (Pubitemid 351809317)
15. Olié V, Canonico M, Scarabin PY. Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women. Curr Opin Hematol 2010;17:457-63.
16. Schenk-Gustafsson K, Brincat M, Erel T, et al. EMAS position statement: managing the menopause in the context of coronary hear disease. Maturitas 2010;68:94-7.
17. Ettinger B, Black DM, Mitlak BH, et al. For the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators, Reduction of vertebral fracture risk in post-menopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized trial. JAMA 1999;282:637-45.
18. Cummings SR, Ettinger B, Delmas PD, et al. for the LIFT Trial investigators. The effects of tibolone in older postmenopausal women. N Engl J Med 2008;359:697-708.
19. Scarabin P, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003;362:428-32. (Pubitemid 36999704)
20. Canonico M, Fournier A, Carcaillon L, et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol 2010;30:340-5.
21. Schneider C, Jick SS, Meier CR. Risk of cardiovascular outcomes in users of estradiol/dydrogesterone or other HRT preparations. Climacteric 2009;12:445-53.
22. Renoux C, Dell'aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: population-based study. J Thromb Haemost 2010;8:979-86.
23. Ohira T, Folsom AR, Cushman M, et al. Reproductive history, hormone replacement, and incidence of venous thromboembolism: the longitudinal investigation of thromboembolism etiology. Br J Haematol 2010;149:606-12.
24. Canonico M, Oger E, Plu-Bureau G, et al. for the Estrogen and Thromboembolism Risk (ESTHER) Study. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007;115:840-5.
25. Lowe GD, Upton MN, Rumley A, et al. Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein - a cross-sectional population survey. Thromb Haemost 2001;86:550-6. (Pubitemid 32743265)
26. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, et al. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women, A randomized controlled trial. Arterioscler Thromb Vasc Biol 1997;17:3071-8. (Pubitemid 28016061)
27. Oger E, Alhenc-Gelas M, Lacut K, et al. Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial. Arterioscler Thromb Vasc Biol 2003;23:1671-6. (Pubitemid 37108215)
28. Bagot CN, Marsh MS, Whitehead M, et al. The effect of estrone on thrombin generation may explain the different thrombotic risk between oral and transdermal hormone replacement therapy. J Thromb Haemost 2010;8:1736-44.
29. Vandenbroucke JP, Koster T, Briet E, et al. Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994;344:1453-7. (Pubitemid 24351698)
30. Rosing J, Middeldorp S, Curvers J, et al. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet 1999;354:2036-40.
31. Hoibraaten E, Mowinckel MC, de Ronde H, Bertina RM, Sandset PM. Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial. Br J Haematol 2001;115:415-20. (Pubitemid 34203511)
32. Post MS, Christella M, Thomassen LG, et al. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women. Arterioscler Thromb Vasc Biol 2003;23:1116-21. (Pubitemid 36713570)
33. Canonico M, Alhenc-Gelas M, Plu-Bureau G, Olie V, Scarabin PY. Activated protein C resistance among postmenopausal women using transdermal estrogens: importance of progestogen. Menopause 2010;17:1122-7.
34. Olie V, Plu-Bureau G, Conard J, et al. Hormone therapy and other risk factors for recurrence of venous thromboembolism among postmenopausal women. Menopause 2010. Dec 21 [Epub ahead of print].
35. Herrington DM, Vittinghoff E, Howard TD, et al. Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease. Arterioscler Thromb Vasc Biol 2002;22:1012-7. (Pubitemid 34655232)
36. Rosendaal FR, Vessey M, Rumley A, et al. Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. Br J Haematol 2002;116:851-4. (Pubitemid 34227006)
37. Lambrinoudaki I, Brincat M, Erel CT, et al. EMAS position statement: management of obese postmenopausal women. Maturitas 2010;66:323-6.
38. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results of the E3N cohort study. Breast Cancer Res Treat 2008;107:103-11. (Pubitemid 350179584)
39. Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet Gynecol 2009;113:65-73.
40. Rexrode K, Manson J. Are some types of hormone therapy safer than others?: lessons from the estrogen and thromboembolism risk study. Circulation 2007;115:820-2.